Literature DB >> 16121597

Internal radionuclide therapy: the ULMDOS software for treatment planning.

Gerhard Glatting1, Michael Landmann, Thomas Kull, Arthur Wunderlich, Norbert M Blumstein, Andreas K Buck, Sven N Reske.   

Abstract

Before therapy with unsealed radionuclides, a dosimetry assessment must be performed for each patient. We present the interactive software tool ULMDOS, which facilitates dosimetric calculations, enhances traceability, and adequate documentation. ULMDOS is developed in IDL 6.1 (Interactive Data Language) under Windows XP/2000. First the patient data, the radiotracer data, and optionally urine and serum data are entered. After loading planar gamma camera images and drawing regions of interest, the residence times can be calculated using fits of the time activity data to exponential functions. Data can be saved in ASCII format for retrospective examination and further processing. ULMDOS allows one to process the dosimetric calculations within a standardized environment, spares the time-consuming transfer of data between different software tools, enables the documentation of ROI and raw data, and reduces intraindividual variability. ULMDOS satisfies the required conditions for traceability and documentation as a prerequisite to routine use in clinical settings.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16121597     DOI: 10.1118/1.1945348

Source DB:  PubMed          Journal:  Med Phys        ISSN: 0094-2405            Impact factor:   4.071


  5 in total

1.  The role of patient-based treatment planning in peptide receptor radionuclide therapy.

Authors:  Deni Hardiansyah; Christian Maass; Ali Asgar Attarwala; Berthold Müller; Peter Kletting; Felix M Mottaghy; Gerhard Glatting
Journal:  Eur J Nucl Med Mol Imaging       Date:  2015-11-18       Impact factor: 9.236

2.  Absorbed dose and biologically effective dose in patients with high-risk non-Hodgkin's lymphoma treated with high-activity myeloablative 90Y-ibritumomab tiuxetan (Zevalin).

Authors:  C Chiesa; F Botta; A Coliva; M Maccauro; L Devizzi; A Guidetti; C Carlo-Stella; E Seregni; M A Gianni; E Bombardieri
Journal:  Eur J Nucl Med Mol Imaging       Date:  2009-05-20       Impact factor: 9.236

3.  Physiologically Based Pharmacokinetic Modeling Is Essential in 90Y-Labeled Anti-CD66 Radioimmunotherapy.

Authors:  Peter Kletting; Christian Maaß; Sven Reske; Ambros J Beer; Gerhard Glatting
Journal:  PLoS One       Date:  2015-05-26       Impact factor: 3.240

4.  Dependence of treatment planning accuracy in peptide receptor radionuclide therapy on the sampling schedule.

Authors:  Christian Maaß; Jan Philipp Sachs; Deni Hardiansyah; Felix M Mottaghy; Peter Kletting; Gerhard Glatting
Journal:  EJNMMI Res       Date:  2016-03-25       Impact factor: 3.138

5.  Towards automated planning for unsealed source therapy.

Authors:  Eduard Schreibmann; Tim Fox
Journal:  J Appl Clin Med Phys       Date:  2012-07-05       Impact factor: 2.102

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.